Sicriptin 1.25 mg Tablets (Bromocriptine)

Product Overview

Sicriptin 1.25 mg Tablets are a prescription medication formulated with bromocriptine mesylate as the active ingredient. Each strip contains ten round, scored tablets delivering a consistent 1.25 milligram dose of the dopamine D2 receptor agonist. The product is manufactured by Serum Institute India, a WHO‑recognized pharmaceutical company with a longstanding reputation for quality assurance in both domestic and international markets. Packaged in a moisture‑resistant strip, the tablets are intended for oral administration and are available in three pack sizes — 30, 60, and 90 tablets — to accommodate varying treatment durations. This formulation is specifically indicated for the management of female infertility associated with hyperprolactinemia, the reduction of elevated prolactin levels, and adjunctive therapy in type 2 diabetes mellitus when glycemic control requires additional dopaminergic modulation.

What is Sicriptin 1.25 mg Tablets

Bromocriptine belongs to the pharmacological class of ergot derivatives and functions primarily as a dopamine D2 receptor agonist. By stimulating dopamine receptors in the hypothalamus, the drug suppresses the synthesis and release of prolactin from lactotroph cells in the anterior pituitary gland. This mechanism leads to a rapid decline in serum prolactin concentrations, which can restore normal ovarian function in women with hyperprolactinemic infertility. In addition to its endocrine applications, bromocriptine exhibits modest hypoglycemic effects through central nervous system pathways that improve insulin sensitivity and decrease hepatic glucose output. The 1.25 mg strength represents the most commonly prescribed dose for the indicated indications and is calibrated to balance efficacy with tolerability.

Uses and Benefits

Clinically, Sicriptin 1.25 mg Tablets are employed to treat conditions where elevated prolactin interferes with ovulation, such as pituitary adenomas, idiopathic hyperprolactinemia, and medication‑induced lactation suppression. In women seeking conception, the medication can increase the likelihood of ovulation and subsequent pregnancy when combined with timed intercourse or assisted reproductive techniques. Beyond reproductive health, the drug is investigated for its role in metabolic disorders; studies cited by the National Institutes of Health (NIH) suggest that intermittent low‑dose bromocriptine can modestly improve glycemic parameters in patients with type 2 diabetes, especially when added to standard oral hypoglycemics. This dual utility makes Sicriptin a valuable option for clinicians who manage patients with overlapping endocrine and metabolic comorbidities.

How It Works

The therapeutic effect of Sicriptin stems from its high affinity for D2 receptors located in the tuberoinfundibular pathway. Activation of these receptors inhibits the release of prolactin, leading to a cascade of downstream hormonal adjustments. In the context of fertility, reduced prolactin levels remove the inhibitory signal on gonadotropin‑releasing hormone (GnRH) neurons, thereby normalizing the pulsatile release of LH and FSH. This restoration enables follicular development and ovulation. Additionally, bromocriptine’s central action modulates sympathetic outflow, which can attenuate hepatic gluconeogenesis and enhance peripheral insulin action. The net result is a dual benefit: improved ovarian cyclicity and modest improvements in blood glucose control, both of which are relevant to diabetes care. For a detailed pharmacological profile, see the Wikipedia entry on bromocriptine (Wikipedia).

Dosage Guidelines

Sicriptin is administered orally, typically once daily, with or without food. The initial recommended dose for most adult women is 1.25 mg taken in the morning, with the possibility of dose escalation to 2.5 mg based on clinical response and tolerability, as outlined in prescribing information from the manufacturer. For patients with renal impairment or those concurrently using other dopamine‑modulating agents, a lower starting dose may be advisable. It is essential that patients do not self‑adjust the dose without medical supervision; regular monitoring of serum prolactin, liver function tests, and blood pressure is recommended to ensure safe and effective therapy. Tablets should be swallowed whole and stored at room temperature, away from moisture and direct sunlight.

Side Effects

Like all dopamine agonists, Sicriptin may be associated with a range of adverse effects. The most frequently reported symptoms include nausea, vomiting, dizziness, headache, and abdominal discomfort, which are generally mild and transient. Less common but clinically significant events comprise orthostatic hypotension, valvular heart disease, and psychiatric manifestations such as hallucinations or impulse‑control disorders. Patients should be alerted to seek immediate medical attention if they experience severe chest pain, sudden vision changes, or signs of allergic reaction such as rash or swelling of the face and throat. Long‑term use may necessitate periodic cardiac evaluation, especially in patients with pre‑existing valvular pathology. For more detailed side‑effect data, refer to Drugs.com.

Warnings and Precautions

Sicriptin is contraindicated in individuals with known hypersensitivity to bromocriptine or any component of the formulation. Caution is advised in patients with a history of cardiac disease, hypertension, or hepatic dysfunction, as dose adjustments may be required. The medication should not be used during pregnancy unless the potential benefit outweighs the risk, and breastfeeding is discouraged due to the possibility of prolactin suppression affecting infant growth. Drug interactions can occur with ergot derivatives, certain antipsychotics, and medications that prolong the QT interval; therefore, a thorough medication reconciliation is recommended before initiation. Finally, abrupt discontinuation is not advised; tapering under medical guidance helps prevent rebound hyperprolactinemia. For official prescribing information, consult the FDA label (U.S. Food and Drug Administration) and additional consumer guidance at MedlinePlus.

Frequently Asked Questions

What condition does Sicriptin 1.25 mg Tablets treat?

Sicriptin is primarily prescribed for women with infertility caused by elevated prolactin levels, a condition known as hyperprolactinemia. It is also used adjunctively in the management of type 2 diabetes to improve glycemic control.

How quickly can I expect improvement in ovulation?

Most patients experience a reduction in serum prolactin within two weeks of starting therapy, and ovulatory function may resume after one to three treatment cycles, depending on the underlying cause and individual response.

Can Sicriptin be taken with other diabetes medications?

Yes, clinical studies have evaluated bromocriptine in combination with metformin and sulfonylureas. However, close monitoring of blood glucose is essential to avoid hypoglycemia, and any dosage adjustments should be made by a healthcare professional.

Is the medication safe for long‑term use?

Long‑term safety data suggest that chronic bromocriptine therapy is generally well tolerated when monitored regularly for cardiac and hepatic function. Periodic evaluation every six to twelve months is recommended for patients on extended regimens.

Where can I purchase authentic Sicriptin tablets?

Sicriptin 1.25 mg Tablets are available through licensed online pharmacies that source directly from Serum Institute India. Look for verified pharmacy seals and ensure that the product packaging displays the manufacturer’s logo and batch information.